Aayush Wellness reports a strong FY26 with revenue hitting Rs 158.09 crore, up 115% year-on-year. While net profit grew by 18% to Rs 3.98 crore, margins faced pressure due to heavy investments in the new Aayush Labs diagnostic platform and infrastructure. The company is pivoting to an integrated preventive healthcare model, moving its registered office to Mumbai to support nationwide expansion.
Aayush Wellness FY26 Revenue Jumps 115% to Rs 158.09 Crore
Net profit rose 18% to Rs 3.98 crore as the company funds its new diagnostic ecosystem.
Reader Takeaway: Revenue scale is aggressive, but monitor if margin compression stabilizes as new diagnostic infrastructure investments mature.
What just happened
Aayush Wellness Ltd has released its Annual Report for FY2025-26, highlighting a pivot from product manufacturing to an integrated preventive healthcare platform. The company shifted its registered office to Mumbai and launched Aayush Labs, a digital diagnostic vertical. Financial performance shows a massive top-line increase to Rs 158.09 crore compared to Rs 73.39 crore in the previous fiscal year.
Why this matters
The company is betting on a "closed-loop" model where diagnostic insights drive demand for its nutraceuticals. By adding Health ATMs and teleconsultation services, Aayush Wellness aims to capture the full patient journey. The 115% revenue growth confirms strong market demand, though the lower 18% growth in net profit reflects the heavy capital expenditure currently weighing on margins.
Governance and Board Updates
Aayush Wellness appointed M/s. A. Raghavendra Rao & Associates as statutory auditors following the resignation of the previous firm in February 2026. Additionally, the company strengthened its board with the appointment of Mr. Dinesh Dhangare and Mr. Kashiram Jadhav as Additional Non-Executive Non-Independent Directors.
Risks to watch
Investors should closely track the net profit margin, which stood at 2.5% for the fiscal year. Management has confirmed that current profitability is impacted by investments in distribution and diagnostic tech. Long-term shareholder value depends on whether these investments achieve operating leverage in the next 12 to 24 months.
What to track next
Watch for the integration efficiency between the new diagnostic arm and the product portfolio. Management will likely prioritize customer acquisition costs and lifetime value metrics as they scale the Health ATM network across the country.